Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Non Operating Income (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Non Operating Income data on record, last reported at $2.9 million in Q4 2025.

  • For Q4 2025, Non Operating Income fell 5.89% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $11.5 million, up 16.06%, while the annual FY2025 figure was $11.5 million, 16.06% up from the prior year.
  • Non Operating Income reached $2.9 million in Q4 2025 per ACRS's latest filing, up from $2.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.1 million in Q4 2024 and bottomed at -$851000.0 in Q3 2021.
  • Average Non Operating Income over 5 years is $1.6 million, with a median of $1.9 million recorded in 2024.
  • Peak YoY movement for Non Operating Income: plummeted 338.66% in 2021, then skyrocketed 1522.47% in 2022.
  • A 5-year view of Non Operating Income shows it stood at $89000.0 in 2021, then soared by 1522.47% to $1.4 million in 2022, then soared by 51.59% to $2.2 million in 2023, then soared by 42.67% to $3.1 million in 2024, then fell by 5.89% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $2.9 million in Q4 2025, $2.5 million in Q3 2025, and $3.0 million in Q2 2025.